Insider Selling: Mirati Therapeutics, Inc. (MRTX) SVP Sells 10,814 Shares of Stock

Mirati Therapeutics, Inc. (NASDAQ:MRTX) SVP Jamie Christensen sold 10,814 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $27.00, for a total transaction of $291,978.00. Following the completion of the sale, the senior vice president now owns 13,691 shares in the company, valued at approximately $369,657. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Jamie Christensen also recently made the following trade(s):

  • On Thursday, January 11th, Jamie Christensen sold 14,725 shares of Mirati Therapeutics stock. The stock was sold at an average price of $22.99, for a total transaction of $338,527.75.
  • On Thursday, November 16th, Jamie Christensen sold 10,275 shares of Mirati Therapeutics stock. The stock was sold at an average price of $18.00, for a total transaction of $184,950.00.
  • On Thursday, November 2nd, Jamie Christensen sold 7,499 shares of Mirati Therapeutics stock. The stock was sold at an average price of $14.00, for a total transaction of $104,986.00.

Shares of Mirati Therapeutics, Inc. (NASDAQ MRTX) traded up $2.20 during trading on Thursday, hitting $27.00. 714,612 shares of the stock traded hands, compared to its average volume of 459,888. The stock has a market cap of $669.44, a PE ratio of -8.68 and a beta of 1.79. Mirati Therapeutics, Inc. has a 1-year low of $2.70 and a 1-year high of $27.85.

Mirati Therapeutics (NASDAQ:MRTX) last issued its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.65) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.81) by $0.16. equities research analysts expect that Mirati Therapeutics, Inc. will post -2.73 earnings per share for the current fiscal year.

Several equities research analysts recently issued reports on MRTX shares. SunTrust Banks restated a “buy” rating and issued a $13.00 target price on shares of Mirati Therapeutics in a report on Monday, October 2nd. Cann restated a “buy” rating and issued a $18.00 target price on shares of Mirati Therapeutics in a report on Monday, January 8th. HC Wainwright restated a “buy” rating and issued a $17.00 target price (down previously from $20.00) on shares of Mirati Therapeutics in a report on Tuesday, November 14th. Oppenheimer restated a “buy” rating and issued a $18.00 target price on shares of Mirati Therapeutics in a report on Wednesday, November 22nd. Finally, BidaskClub upgraded shares of Mirati Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $14.75.

Several institutional investors have recently modified their holdings of the company. Sabby Management LLC boosted its stake in shares of Mirati Therapeutics by 2.1% during the 2nd quarter. Sabby Management LLC now owns 255,100 shares of the biotechnology company’s stock worth $921,000 after acquiring an additional 5,365 shares during the last quarter. Susquehanna International Group LLP raised its position in shares of Mirati Therapeutics by 46.5% during the 2nd quarter. Susquehanna International Group LLP now owns 50,509 shares of the biotechnology company’s stock valued at $184,000 after purchasing an additional 16,030 shares during the period. Citadel Advisors LLC bought a new stake in shares of Mirati Therapeutics during the 3rd quarter valued at $268,000. OxFORD Asset Management LLP bought a new stake in shares of Mirati Therapeutics during the 3rd quarter valued at $365,000. Finally, PDT Partners LLC bought a new stake in shares of Mirati Therapeutics during the 2nd quarter valued at $200,000. Institutional investors and hedge funds own 64.68% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Insider Selling: Mirati Therapeutics, Inc. (MRTX) SVP Sells 10,814 Shares of Stock” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/01/18/insider-selling-mirati-therapeutics-inc-mrtx-svp-sells-10814-shares-of-stock.html.

About Mirati Therapeutics

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Insider Buying and Selling by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply